Lisanti Capital Growth LLC Decreases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Lisanti Capital Growth LLC reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 25.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 175,470 shares of the biotechnology company’s stock after selling 59,565 shares during the period. Lisanti Capital Growth LLC’s holdings in ADMA Biologics were worth $3,009,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ADMA. New York State Teachers Retirement System purchased a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $1,821,000. Janney Montgomery Scott LLC acquired a new position in ADMA Biologics in the 3rd quarter worth approximately $1,454,000. Robeco Institutional Asset Management B.V. increased its holdings in ADMA Biologics by 61.2% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 179,084 shares of the biotechnology company’s stock worth $3,580,000 after buying an additional 68,000 shares during the period. Amalgamated Bank increased its holdings in ADMA Biologics by 803.0% in the 3rd quarter. Amalgamated Bank now owns 68,169 shares of the biotechnology company’s stock worth $1,363,000 after buying an additional 60,620 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 4.4 %

NASDAQ ADMA opened at $16.91 on Friday. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $16.67 and its 200-day simple moving average is $17.96. The firm has a market cap of $4.00 billion, a PE ratio of 60.39 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ADMA shares. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.